全髋或全膝关节置换术前口服铁补充是否有作用
分析3435例全关节置换术(1461例全髋、1974例全膝)在两阶段血液保护方案中的效果,第二阶段加入术前口服铁剂。口服铁剂使髋、膝队列术前血红蛋白分别升高6 g/L和7 g/L(均P<.001),血清铁蛋白分别升高80 μg/L和52 μg/L(均P<.001),并降低了促红细胞生成素和静脉铁的使用率。结论认为口服铁剂减轻了围手术期贫血负担并减少了其他血液保护疗法的使用。
要点
- 口服铁剂使全髋和全膝队列术前血红蛋白分别升高6 g/L和7 g/L(均P<.001)。
- 口服铁剂使全髋和全膝队列血清铁蛋白分别升高80 μg/L和52 μg/L(均P<.001)。
- 促红细胞生成素使用率在全髋从16%降至6%、全膝从18%降至6%(均P<.001)。
核心结论
- 口服铁剂治疗减轻了全髋和全膝关节置换术前的围手术期贫血负担,并减少了其他血液保护疗法的使用。
- 未来研究应阐明口服铁剂治疗的成本效益。
研究设计与样本
- 对3435例全关节置换术(1461例全髋关节置换术和1974例全膝关节置换术)在血液保护方案两个阶段中的分析。
- 第一阶段对存在围手术期贫血风险的患者使用促红细胞生成素α或静脉铁剂。
- 第二阶段除上述干预外,还包括术前口服铁剂补充。
主要发现
- 口服铁剂使全髋队列术前血红蛋白升高6 g/L(P<.001),全膝队列升高7 g/L(P<.001)。
- 口服铁剂使全髋队列血清铁蛋白升高80 μg/L(P<.001),全膝队列升高52 μg/L(P<.001)。
- 血红蛋白<130 g/L的患者数量在两个队列中均显著减少(均P<.001)。
- 血清铁蛋白<35 μg/L的患者数量在全髋队列减少(P=.002),全膝队列减少(P<.001)。
- 促红细胞生成素使用率在全髋从16%降至6%(P<.001),全膝从18%降至6%(P<.001);静脉铁使用率在全髋从4%降至2%(P=.05),全膝从5%降至2%(P<.001)。
关键数值与推荐
- 全髋队列术前血红蛋白升高6 g/L(P<.001),全膝队列升高7 g/L(P<.001)。
- 全髋队列血清铁蛋白升高80 μg/L(P<.001),全膝队列升高52 μg/L(P<.001)。
- 血红蛋白<130 g/L患者数量在全髋和全膝队列均显著减少(均P<.001)。
- 血清铁蛋白<35 μg/L患者数量在全髋队列减少(P=.002),全膝队列减少(P<.001)。
- 促红细胞生成素使用率在全髋从16%降至6%(P<.001),全膝从18%降至6%(P<.001);静脉铁使用率在全髋从4%降至2%(P=.05),全膝从5%降至2%(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several treatment modalities exist for the treatment of perioperative anemia. We determined the effect of oral iron supplementation on preoperative anemia, and the use of blood-conserving interventions before total hip arthroplasty (THA) and total knee arthroplasty (TKA). METHODS: A total of 3435 total joint arthroplasties (1461 THAs and 1974 TKAs) were analyzed during 2 phases of a blood conservation program. The first phase used erythropoietin alfa (EPO) or intravenous (IV) iron for patients at risk for perioperative anemia. The second phase included these interventions, as well as preoperative iron supplementation. The effect on preoperative hemoglobin (Hb) and serum ferritin, as well as EPO and IV iron utilization, was determined. RESULTS: Oral iron therapy increased preoperative Hb level by 6 g/L (P < .001) and 7 g/L (P < .001) in the hip and knee cohorts, respectively. Serum ferritin level rose by 80 μg/L (P < .001) and 52 μg/L (P < .001) in the hip and knee cohorts, respectively. The number of patients with an Hb level <130 g/L was significantly reduced (P < .001 for both cohorts), as were patients with serum ferritin levels <35 μg/L (P = .002 for hip and P < .001 for knee cohorts). Utilization of EPO reduced from 16% to 6% (P < .001) and 18% to 6% (P < .001) in the hip and knee cohorts, respectively. Utilization of IV iron reduced from 4% to 2% (P = .05) and 5% to 2% (P < .001) in the hip and knee cohorts, respectively. CONCLUSION: Oral iron therapy reduced the burden of perioperative anemia and reduced utilization of other blood-conserving therapies before THA and TKA. Future research should delineate the cost-effectiveness of oral iron therapy.
引用
- Petis SM, Lanting BA, Vasarhelyi EM, et al. Is There a Role for Preoperative Iron Supplementation in Patients Preparing for a Total Hip or Total Knee Arthroplasty? J Arthroplasty. 2017. PMID: 28529107. doi:10.1016/j.arth.2017.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。